These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11477319)

  • 1. Removal of 10-hydroxycarbazepine by plasmapheresis.
    Christensen J; Balslev T; Villadsen J; Heinsvig EM; Dam M; Poulsen JH
    Ther Drug Monit; 2001 Aug; 23(4):374-9. PubMed ID: 11477319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of oxcarbazepine.
    May TW; Korn-Merker E; Rambeck B
    Clin Pharmacokinet; 2003; 42(12):1023-42. PubMed ID: 12959634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
    Antunes NJ; van Dijkman SC; Lanchote VL; Wichert-Ana L; Coelho EB; Alexandre Junior V; Takayanagui OM; Tozatto E; van Hasselt JGC; Della Pasqua O
    Eur J Pharm Sci; 2017 Nov; 109S():S116-S123. PubMed ID: 28528287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy.
    Wang Y; Zhang HN; Niu CH; Gao P; Chen YJ; Peng J; Liu MC; Xu H
    Acta Pharmacol Sin; 2014 Oct; 35(10):1342-50. PubMed ID: 25220641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the clinical pharmacokinetics of oxcarbazepine.
    Flesch G
    Clin Drug Investig; 2004; 24(4):185-203. PubMed ID: 17516704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of oxcarbazepine and its monohydroxy derivative in epileptic children.
    Rodrigues C; Chiron C; Rey E; Dulac O; Comets E; Pons G; Jullien V
    Br J Clin Pharmacol; 2017 Dec; 83(12):2695-2708. PubMed ID: 28771787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
    Antunes Nde J; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Tozatto E; Marques MP; Lanchote VL
    Eur J Clin Pharmacol; 2016 Feb; 72(2):195-201. PubMed ID: 26514967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS: application in a pharmacokinetic study.
    de Jesus Antunes N; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre V; Takayanagui OM; Tozatto E; Lanchote VL
    Chirality; 2013 Dec; 25(12):897-903. PubMed ID: 24123382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of unbound plasma concentration of oxcarbazepine and the 10-hydroxycarbazepine enantiomers by liquid chromatography with tandem mass spectrometry in healthy volunteers.
    Antunes NJ; Wichert-Ana L; Coelho EB; Della Pasqua O; Alexandre Junior V; Takayanagui OM; Marques MP; Lanchote VL
    J Pharm Biomed Anal; 2018 Feb; 149():442-447. PubMed ID: 29169112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of oral loading of oxcarbazepine suspension in selected patients with epilepsy.
    Kim DW; Gu N; Lee H; Jang IJ; Chu K; Yu KS; Cho JY; Yoon SH; Na HJ; Lee SK
    Int J Clin Pharmacol Ther; 2013 Oct; 51(10):780-6. PubMed ID: 23849326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy.
    Rey E; Bulteau C; Motte J; Tran A; Sturm Y; D'Souza J; Markabi S; Pons G; Dulac O
    J Clin Pharmacol; 2004 Nov; 44(11):1290-300. PubMed ID: 15496647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects.
    Volosov A; Xiaodong S; Perucca E; Yagen B; Sintov A; Bialer M
    Clin Pharmacol Ther; 1999 Dec; 66(6):547-53. PubMed ID: 10613609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy.
    Yu Y; Zhang Q; Xu W; Lv C; Hao G
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):345-51. PubMed ID: 25700977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD).
    Miles MV; Tang PH; Ryan MA; Grim SA; Fakhoury TA; Strawsburg RH; DeGrauw TJ; Baumann RJ
    Ther Drug Monit; 2004 Jun; 26(3):300-4. PubMed ID: 15167632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology and pharmacokinetics of oxcarbazepine.
    Lloyd P; Flesch G; Dieterle W
    Epilepsia; 1994; 35 Suppl 3():S10-3. PubMed ID: 8156973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of UGT1A9 genetic polymorphisms on monohydroxylated derivative of oxcarbazepine concentrations and oxcarbazepine monotherapeutic efficacy in Chinese patients with epilepsy.
    Lu Y; Fang Y; Wu X; Ma C; Wang Y; Xu L
    Eur J Clin Pharmacol; 2017 Mar; 73(3):307-315. PubMed ID: 27900402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy.
    Chen CY; Zhou Y; Cui YM; Yang T; Zhao X; Wu Y
    J Clin Pharm Ther; 2019 Apr; 44(2):300-311. PubMed ID: 30636182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetic variability of oxcarbazepine in epileptic patients].
    Viola MS; Bercellini MA; Saidón P; Rubio MC
    Medicina (B Aires); 2000; 60(6):914-8. PubMed ID: 11436701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the bioequivalence of two oxcarbazepine oral suspensions versus a film-coated tablet in healthy subjects.
    Flesch G; Tudor D; Denouel J; Bonner J; Camisasca R
    Int J Clin Pharmacol Ther; 2003 Jul; 41(7):299-308. PubMed ID: 12875346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.
    Yang X; Yan Y; Fang S; Zeng S; Ma H; Qian L; Chen X; Wei J; Gong Z; Xu Z
    Medicine (Baltimore); 2019 Mar; 98(12):e14908. PubMed ID: 30896644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.